actigraphy device axivity model ax3  (Axivity Ltd)

Journal: Frontiers in Neuroscience

Article Title: Association Between Sleep Duration and Parkinson’s Disease Varied Across Related Orphan Receptor A rs2028122 Genotypes

doi: 10.3389/fnins.2022.902895

Figure Lengend Snippet: Baseline characteristics of the UK Biobank population, separated by Parkinson’s disease.

Article Snippet: Actigraphy devices (Axivity AX3) were worn 2.8–9.7 years after the study baseline from the UK Biobank for up to 7 days.

Techniques: Activity Assay

Journal: Journal of Parkinson's Disease

Article Title: Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia

doi: 10.3233/JPD-213126

Figure Lengend Snippet: Digital biomarker compliance. A) Actigraphy compliance during the intervention period. The number of compliant participants on each day is shown within the bars. B) Overall iPad Trial app compliance including data by all participants, whereas compliance removing data from participants who discontinued the study is shown in C).

Article Snippet: The actigraphy device (AX3-axivity device: https://axivity.com/product/ax3 ), uses an accelerometer to measure activity and, similar to a watch, was placed on the non-dominant wrist of eligible participants (US-based and English-speaking) at specified visits for a 2-week period until the subsequent clinic visits to allow continuous tracking of sleep and activity during these periods.

Techniques: Biomarker Discovery

Journal: Journal of Parkinson's Disease

Article Title: Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia

doi: 10.3233/JPD-213126

Figure Lengend Snippet: Key actigraphy (A–C) and trial app (D–F) outcomes. A) Actigraphy measurements detected a dose-dependent reduction in daytime sleep using the actigraphy watch during intervention (visit 9) returning to pre-intervention levels post-intervention. B) Nighttime sleep showed minimal changes. iPad trial assessments were performed throughout the study. C) A mevidalen-induced increase in a daily activity in walking minutes per day was observed during intervention (75 mg group). D) Mevidalen treatment showed minimal changes to DSST performance. E) A mevidalen-induced increase (30 mg group) was observed in SWM. F) Minimal treatment effects were observed in the finger tapping tests. Type 1 errors were not controlled for, and p -values were not adjusted. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: The actigraphy device (AX3-axivity device: https://axivity.com/product/ax3 ), uses an accelerometer to measure activity and, similar to a watch, was placed on the non-dominant wrist of eligible participants (US-based and English-speaking) at specified visits for a 2-week period until the subsequent clinic visits to allow continuous tracking of sleep and activity during these periods.

Techniques: Activity Assay

Journal: Journal of Parkinson's Disease

Article Title: Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia

doi: 10.3233/JPD-213126

Figure Lengend Snippet: Digital biomarkers such as actigraphy allow for continuous data capture. A) Daily sleep. Reduction in total daytime sleep every day at all doses relative to placebo at steady state, with return to baseline post-intervention. B) Hourly sleep. Reduction in daytime sleep/inactivity from 9am to 3pm at all doses relative to placebo. C) Daily activity. Increase in average acceleration (m-g) every day at all doses relative to placebo at steady state, with return to baseline post-intervention. D) Hourly activity. Increase in average acceleration (m-g) from 9am to 7pm at all doses relative to placebo. Night in this study was defined as 7pm to 9am. X-axis break in A) and C) indicates the several weeks between intervention and post-intervention as per study schematic showing the PRESENCE trial period and the use of digital devices in Fig. 1 .

Article Snippet: The actigraphy device (AX3-axivity device: https://axivity.com/product/ax3 ), uses an accelerometer to measure activity and, similar to a watch, was placed on the non-dominant wrist of eligible participants (US-based and English-speaking) at specified visits for a 2-week period until the subsequent clinic visits to allow continuous tracking of sleep and activity during these periods.

Techniques: Activity Assay

Journal: Journal of Parkinson's Disease

Article Title: Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia

doi: 10.3233/JPD-213126

Figure Lengend Snippet: Clinical relevance of digital measures at baseline. Correlations between clinical assessments and Actigraphy (A and B) and iPad trial (C and D) assessments. A) Actigraphy-measured daytime sleep positively correlates with Epworth Sleepiness Scale score. B) Physical activity correlates with improvement on MDS-UPDRS Part II. C) Better scores of SWM correlate with lower ADAS-Cog 13 . D) Better scores of DSST correlate with lower ADAS-Cog 13 . ADAS-Cog 13 , Alzheimer Disease Assessment Scale –Cognitive 13-Item Scale; DSST, digital symbol substitution; MDS, Movement Disorder Society–owned rating scales; SWM, spatial working memory; UPDRS, Unified Parkinson Disease Rating Scale.

Article Snippet: The actigraphy device (AX3-axivity device: https://axivity.com/product/ax3 ), uses an accelerometer to measure activity and, similar to a watch, was placed on the non-dominant wrist of eligible participants (US-based and English-speaking) at specified visits for a 2-week period until the subsequent clinic visits to allow continuous tracking of sleep and activity during these periods.

Techniques: Activity Assay